RA Capital Management

Last year, #Science2Startup brought together academic researchers, entrepreneurs, industry leaders, and venture capitalists for a dynamic exchange of ideas. The symposium showcased eight exceptional scientists from leading global research institutions, all working on pioneering advancements in science. To learn more about the event or to get involved for our 2025 event this May, please email us at [email protected] or visit www.science2startup.com. ? #biotech #pharma #startup

The team at Superluminal Medicines Inc. is working to transform how medicines are created with their generative biology, chemistry, and machine learning platform. We were excited to lead their?recent $120 million Series A funding round,?with participation from Insight Partners, nVentures (NVIDIA), Gaingels, and new investors Catalio Capital Management, Eli Lilly and Company, and Cooley LLP.?We?look forward to Superluminal Medicines Inc. continuing their important work!

Ever stumble into something and think “holy ****, how does everyone not realize this is here?” That’s what gateway.racap.com is for biotech executives/directors and everyone who wants to be one. It’s still an emerging gem where my colleagues and I have been storing pearls in the form of interviews and articles and slide decks that explain countless things about biotech. You can even assess the strength of your board across 20+ dimensions & discover people who could fill gaps. Learn how to run efficient board meetings (shave 4 hours down to 1-2; hint: elephant slide, core value prop, and agenda), how low fees could be on financing instruments, real differences between crossover and other rounds, how to teach value of equity to employees, how to extract from your existing investors what they really want to invest in an IPO and at what price, how to handle M&A negotiations, the utility of low-ego polymaths, how to avoid overstaffing, and so much more. When we learn new things, Gateway is where we share what we learn. And if you have something you want to teach, just let me know. Gateway features the wisdom of many people from across our ecosystem. I wrote “The Entrepreneur’s Guide to a Biotech Startup” 20 years ago. Gateway is the ever evolving sequel. Hope you discover it (if you haven’t already) and pass it onto to others. Because we all make fewer mistakes when we learn from others. And with society demanding that we do more with less, there’s really no excuse for repeating mistakes, right? Peter #biotech RA Capital Management

Congratulations to the team at Vesta Healthcare! We were excited to lead this financing, and we look forward to their continued work to improve healthcare outcomes for those with home care needs.

We are excited to announce the first acquisition of a fully-baked company from RA Capital's RAVen (RA Ventures) incubator - congratulations to the Mariana Oncology team! You can read more about how RAVen helped build the company that became Mariana in the RApport article below. https://lnkd.in/eQmjvZQu

Celebrating #EarthWeek at the White House! RA Capital Management’s General Counsel Sarah Reed and I were thrilled to be involved in the development of the US-BOLT (University Startup Basic-Out-Licensing) term sheet for climate-related startups spinning out of universities. The goal of the work is to make it easier for universities and start-up companies to collaborate on the commercialization of game-changing technologies. Together with the work group led by Orin Herskowitz, the White House Office of Science and Technology Policy celebrated the completion of this effort with fellow professionals, policymakers, and innovators, all dedicated to driving positive change for our planet. We are excited to have the US-BOLT Climate term sheet now available to the community on the NVCA website here: https://lnkd.in/e5hsXfQw Joshua Posamentier (Congruent); Manny Stockman and Kirsten Leute (OUP); Gabriel Kra and Carly Anderson (Prelude); Christina Karapataki (Breakthrough Energy Ventures); Orin Herskowitz and Dovina Qu (Columbia); Case Cortese and Rosemary Kiser (Caltech); Deirdre Zammit (MIT); Jordan Grant and Sam Liss (Harvard); Fiona Wills (University of Washington); Jonathan Gortat, MBA, CLP (Stanford); Anthony Williams (Princeton); Laleh Shayesteh (Berkeley); Geoffrey Spolyar (Cooley); Sarah A. Solomon (Goodwin): Miranda Biven, Barath Chari, Manja Sachet, Farah Gerdes (Wilson Sonsini)

Thank you, Kendalle Burlin O'Connell, Esq. and the MassBio team for convening such an inspirational and informative day #StateOfPossible2024! I was honored to speak with an engaged audience about how Massachusetts can lengthen its lead as the center of biomedical innovation by inspiring “fans” with our quests to develop new therapies and being a model for insurance reform.? Great messages from my fellow speakers including Governor Maura Healey, Congressman Jake Auchincloss, Biotechnology Innovation Organization John F. Crowley, Reshma Kewalramani, MD FASN, CEO of Vertex Pharmaceuticals, and former NFL player and advocate Devin McCourty. Together, we make Massachusetts the state where innovation happens! #biomedicalinnovation #biotech #massbio #stateofpossible #creatingfans RA Capital Management Peter Kolchinsky

It was a full house yesterday at the Broad Institute of MIT and Harvard for our 2024 #Science2Startup symposium. Thank you to everyone who joined us for a day filled with insightful presentations, engaging panel discussions, and valuable networking opportunities centered around the future of the #biotech industry. ? Boston's vibrant #lifescience ecosystem makes this an unparalleled hub for innovation and we are thrilled to continue our efforts to drive scientific breakthroughs and entrepreneurial ventures forward. On the RA team, we'd specifically like to thank Joshua Resnick for participating as an Advisor and?Rebecca Silberman, Jenna Hebert, PhD, and?Jessica Sagers, PhD for their work on the Steering Committee. ? Stay tuned for details on next year's event! ? Atlas Venture │ 5AM Ventures │ Osage University Partners (OUP) │ RA Capital Management │ MassBio │ Colliers │ Deloitte │ Evotec │ Goodwin │ Pliancy │ Silicon Valley Bank

The 2024 #Science2Startup symposium is tomorrow! After exciting discussions and powerful networking, eight researchers will present their ideas and interact with leading investors and executives in the Boston #biotech hub. Thank you to our other event hosts F-Prime Capital, Atlas Venture, 5AM Ventures, Osage University Partners (OUP), and MassBio. Make sure to follow along for updates!

We are delighted to welcome David R. Liu, Ph.D. to lead our fireside chat at this year’s #Science2Startup symposium in Cambridge, MA on April 10th.? ? Liu is the Richard Merkin Professor, Director of the Merkin Institute of Transformative Technologies in Healthcare, and Vice-Chair of the Faculty at the Broad Institute of MIT and Harvard; Thomas Dudley Cabot Professor of the Natural Sciences & Professor of Chemistry and Chemical Biology at Harvard University; and Howard Hughes Medical Institute Investigator. ? His major research interests include the engineering, evolution, and in vivo delivery of genome editing agents to study and treat genetic diseases; the evolution of novel therapeutic proteins using phage-assisted continuous evolution (PACE); and the discovery of bioactive synthetic molecules using DNA-templated organic synthesis and DNA-encoded libraries. ? As a business leader, he has successfully launched, led and scaled companies and products in the #healthcare space. ? Learn more about Science2Startup, a unique event where entrepreneurs and researchers in the biotech space can meet, collaborate, and learn from one another: www.science2startup.com ? If you'd like to get involved, email us at: [email protected]